Welcome to our dedicated page for TriSalus Life Sciences SEC filings (Ticker: TLSI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
TriSalus Life Sciences, Inc. filings document operating results, governance actions and capital-structure matters for an oncology-focused medical technology company. Form 8-K reports cover financial results, business updates, guidance, material events, leadership changes, board composition and Regulation FD disclosures tied to TriNav, PEDD and related oncology development activity.
Proxy materials describe shareholder voting matters, director elections, board committees, executive compensation and equity awards. The filing record also includes capital-structure disclosures for common stock and warrants, material-agreement categories, clinical or regulatory disclosure topics and risk-related information associated with commercializing PEDD infusion systems and developing investigational therapies for solid tumors.
Form 4 Overview – TriSalus Life Sciences, Inc. (TLSI)
Director Mats Wahlstrom reported an acquisition of derivative securities on 12 June 2025. The filing records a grant of 15,000 non-qualified stock options (‘Director Stock Option – right to buy’) with an exercise price of $5.50 per share. These options will fully vest on the earlier of (i) the one-year anniversary of the grant date or (ii) the next annual shareholder meeting, contingent upon continued board service.
Following this grant, Mr. Wahlstrom now holds a total of 200,945 derivative securities (options) in a direct ownership capacity. No common shares were bought or sold, and no cash consideration exchanged hands at the time of the grant. The option’s expiration date is 11 June 2035, providing a 10-year exercise window once vested.
This transaction represents routine director compensation and does not alter the company’s outstanding share count or cash position. It signals continued alignment of the director’s incentives with shareholder returns but is not expected to have a material impact on TLSI’s near-term financials or market valuation.
TriSalus Life Sciences, Inc. (Nasdaq: TLSI) filed an 8-K to announce the launch of a dual exchange offer and consent solicitation aimed at retiring its outstanding Series A Convertible Preferred Stock. Holders who tender will receive a number of common shares equal to the sum of the preferred share’s Liquidation Preference plus all accrued dividends through August 10, 2027, divided by $4.00 per share. The company is offering up to 11,860,206 new common shares in total.
Concurrently, TriSalus seeks holder approval to amend the Certificate of Designations so that any preferred shares not exchanged can be mandatorily converted at a ratio that is 11.3 % less favorable than the voluntary exchange ratio. Investors representing approximately 55 % of outstanding preferred shares have already executed Tender and Support Agreements, effectively securing majority backing for both the exchange and the amendment, provided other conditions are met.
The offer began on June 23, 2025 and is scheduled to expire one minute after 11:59 p.m. EST on July 23, 2025, unless extended. Preferred holders may withdraw tenders any time before expiration. The transaction is being effected through a Form S-4 registration statement and Schedule TO filed the same day; investors are urged to review these filings for full terms and risk factors.
If completed, the exchange would eliminate a cumulative dividend obligation, simplify the capital structure, and remove an overhang that could impede future financing. However, it will also dilute existing common shareholders by up to roughly 25 % of the current basic share count, subject to final participation levels.
TriSalus Life Sciences, Inc. (TLSI) has filed a Form S-4 registration statement connected with a planned business combination. The excerpt provided is an XBRL tag listing that identifies numerous financial instruments and contractual arrangements but does not include any numerical values, pro-forma financials, or narrative description of the transaction.
Key elements referenced in the tags include:
- Standby Equity Purchase Agreement (SEPA) – suggests an equity financing back-stop to raise capital post-combination.
- Secured loan facilities with multiple maturity dates (June 30 2025 and December 31 2025) and association with OrbiMed, indicating the presence of debt financing.
- Extensive warrant structures (public, private, working-capital, SPAC, OrbiMed) and contingent earn-out liabilities, highlighting potential future dilution and performance-linked payouts.
- Derivative liabilities linked to the SEPA and warrants, implying fair-value accounting requirements.
- Tags for fair-value hierarchy levels 1 and 2, measurement inputs (share price, volatility, risk-free rate), and subsequent events dated through 30 April 2025.
- Mentions of revision of prior-period errors, indicating restatement activity, and Tags for preferred stock, common stock, and paid-in capital balances.
The filing appears highly complex—with numerous financing instruments, derivative features, and revisions—yet the excerpt lacks the monetary amounts or the terms necessary to quantify dilution, leverage, or valuation impact. Investors will need the full S-4 narrative and financial tables (not included here) to evaluate the transaction’s economics, pro-forma ownership, and forward-looking risks.